Roche is hoping its Tecentriq will be the first immunotherapy approved in tough-to-treat breast cancer, after it stayed the spread of "triple negative" disease in a phase 3 trial. When combined with Celgene’s chemotherapy Abraxane (nab-paclitaxel)...
Original Article: Roche to file Tecentriq in triple negative breast cancer